COMMUNIQUÉS West-GlobeNewswire

Epizyme to Present New Tazemetostat Data at the American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) Congress

17/05/2018 - 15:13

Company to Host Investor Conference Call Today at 9:30 a.m. EDT CAMBRIDGE, Mass., May 17, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ: EPZM ), a clinical-stage company developing novel epigenetic therapies, announced [...]

TG Therapeutics, Inc. Announces Upcoming Data Presentations at the 54th Annual Meeting of the American Society of Clinical Oncology and the 23rd Congress of the European Hematology Association

17/05/2018 - 15:10

NEW YORK, May 17, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX ), today announced that abstracts featuring umbralisib (TGR-1202), the Company's once-daily PI3K delta inhibitor, and TG-1701, the Company’s [...]

Geron Announces Oral Presentation at European Hematology Association Congress

17/05/2018 - 15:05

Updated Imetelstat Clinical Data from Part 1 of IMerge in Myelodysplastic Syndromes to be Presented MENLO PARK, Calif., May 17, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN ) today announced that an abstract [...]

HempAmericana Begins Bottling and Distribution Phase for 99% Pure CBD Isolate Production

17/05/2018 - 15:03

NEW YORK, May 17, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire – HempAmericana, Inc. (OTC:HMPQ) (“HempAmericana” or the “Company”) is excited to announce that it is in the final testing stage of specialized bottling [...]

Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer

17/05/2018 - 15:00

Results from the Kisqali ® MONALEESA clinical trial program, the largest industry- sponsored Phase III registration program researching a CDK4/6 inhibitor in HR+/HER2- advanced breast cancer, will be presented at ASCO [...]

Ceapro Inc. Reports 2018 First Quarter Results

17/05/2018 - 15:00

EDMONTON, Alberta, May 17, 2018 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO ) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for [...]

Atara Biotherapeutics to Present Long-Term Tab-cel™ Phase 2 Clinical Outcomes for Patients with Epstein-Barr Virus Associated Post-Transplant Lymphomas at 23rd Congress of European Hematology Association

17/05/2018 - 15:00

SOUTH SAN FRANCISCO, Calif., May 17, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA ), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with [...]

Trading by management and close relations of management

17/05/2018 - 14:54

Read the full announcement in the attached file Attachment 2018_34_Trading_by_management_EN

SELLAS Life Sciences to Present Phase 1/2 Clinical Data of Galinpepimut-S (GPS) in Ovarian Cancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

17/05/2018 - 14:45

Clinical and Regulatory Advisory Board Meetings for NeuVax in Triple Negative Breast Cancer on May 30, and May 31, 2018 NEW YORK, May 17, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group Inc., (Nasdaq: SLS ) (SELLAS [...]

Esperite NV (ESP) with The Cell Factory has signed the agreement with the PHARM CRO to start preparation for the first-in-man clinical trials in treatment of Crohn's disease.

17/05/2018 - 14:33

Amsterdam, The Netherlands -17 th May 2018 Esperite's The Cell Factory has signed today the agreement with PHARM, the Italian CRO company which is preparing for the first-in-man clinical trials using CF-MEV-107 EVs. A [...]

Golden Leaf Holdings Signs Letter of Intent to Acquire Nevada and California Cannabis Cultivation Facilities

17/05/2018 - 14:32

Transaction would accelerate build-out of vertically integrated model in high-growth target markets TORONTO, May 17, 2018 (GLOBE NEWSWIRE) -- Golden Leaf Holdings Ltd. (“Golden Leaf” or the “Company”) (CSE:GLH) (OTCQB: [...]

Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of Crysvita® (burosumab) Treatment to Oral Phosphate and Active Vitamin D in Children with X-Linked Hypophosphatemia (XLH)

17/05/2018 - 14:30

Substantial Healing of Rickets Observed in 72% of Patients Treated with Crysvita Compared to 6% of Patients Receiving Conventional Therapy at 40 Weeks NOVATO, Calif. and TOKYO and LONDON, May 17, 2018 (GLOBE NEWSWIRE [...]

Nuvectra to Present at Two Upcoming Investor Conferences

17/05/2018 - 14:30

PLANO, Texas, May 17, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR ), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief [...]

SB208 Increases Daily Nail Growth Rate over Four Weeks of Treatment

17/05/2018 - 14:05

Novan to Present Clinical Data from SB208 Onychomycosis Development Program at International Investigative Dermatology Meeting MORRISVILLE, N.C., May 17, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") ( [...]

BioDelivery Sciences Announces Agreement with Broadfin Capital on Comprehensive Plan to Strengthen Business

17/05/2018 - 14:01

$50 Million Equity Financing Led By Broadfin Announced Separately Today Three New Independent Directors Selected by Broadfin Added To Board; Four Current Independent Directors Retiring Amends Senior Credit Facility with [...]

BioDelivery Sciences Announces Pricing of $50 Million Equity Financing

17/05/2018 - 14:01

RALEIGH, N.C., May 17, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI ) today announced that it has entered into definitive agreements with existing institutional and other accredited [...]

BioSyent Schedules Q1 2018 Earnings Release for May 30, 2018

17/05/2018 - 14:00

TORONTO, May 17, 2018 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”) (TSX Venture:RX) will be reporting its financial results for the first quarter ended March 31, 2018 on Wednesday, May 30, 2018. A [...]

Journal of Clinical Psychiatry Publishes Positive Results of Cognitive Performance From Phase 2B Trial of Roluperidone, Under Development by Minerva Neurosciences for the Treatment of Negative Symptoms in Schizophrenia

17/05/2018 - 14:00

WALTHAM, Mass., May 17, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV ), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders [...]

Celtaxsys Announces Last Patient, Last Visit in Landmark CF Phase 2b Lung Function Preservation Trial, Clinical Results Expected in July

17/05/2018 - 14:00

-Phase 2b Trial Design and Enrolled Patient Demographics to be Presented at the 41st European Cystic Fibrosis Society Conference ATLANTA, May 17, 2018 (GLOBE NEWSWIRE) -- Celtaxsys, Inc., a clinical stage pharmaceutical [...]